Aurobindo Pharma Share Price Today (AUROPHARMA)
TODAY IN ONE LINE
AUROPHARMA fell 2.8% on average volume, lagging Nifty's -0.7% move.
With a market cap of ₹88,346.4 Cr., it trades at a P/E of 26.03. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Aurobindo Pharma flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 20.3%
- ●High Promoter HoldingPromoters hold 51.8% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Aurobindo Pharma News
What changed recently?
Recent events, corporate actions, and announcements.
Aurobindo Pharma Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Aurobindo Pharma Limited, framed against the sector median so the premium or discount is obvious at a glance.
Aurobindo Pharma Limited trades at a P/E of 26.03× and P/B of 2.41×, against the Healthcare sector median P/E of 40.48×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Aurobindo Pharma Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Aurobindo Pharma Limited — derived from the live tape, not yesterday's close.
Aurobindo Pharma Limited last traded at ₹1,536.2 with an intraday range of ₹1,515–₹1,564 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1536.20| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1659.80 | +123.60 | +8.05% |
| R3 | 1610.80 | +74.60 | +4.86% |
| R2 | 1587.40 | +51.20 | +3.33% |
| R1 | 1561.80 | +25.60 | +1.67% |
| PIVOT | 1538.40 | 2.20 | 0.14% |
| CURRENT | 1536.20 | — | — |
| S1 | 1512.80 | -23.40 | -1.52% |
| S2 | 1489.40 | -46.80 | -3.05% |
| S3 | 1463.80 | -72.40 | -4.71% |
| S4 | 1414.80 | -121.40 | -7.90% |
AUROPHARMA is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹1532.5–₹1564
Trading Below opening range, showing Bearishness
Aurobindo Pharma Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Aurobindo Pharma Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Aurobindo Pharma Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹88,346.4 Cr. and reported EPS of ₹60.36.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 31,724 | 33,653 ▲ 6.1% |
| Sales Growth YoY %Derived | 9.39% | 6.08% |
| Other Income | 622 | 492 ▼ 20.9% |
| Total Income | 32,346 | 34,145 ▲ 5.6% |
| 13,026 | 13,488 ▲ 3.5% | |
| Gross ProfitDerived | 18,697 | 20,165 ▲ 7.8% |
| Gross Margin %Derived | 58.94% | 59.92% |
| 12,115 | 13,319 ▲ 9.9% | |
| EBITDA (Operating Profit)Derived | 6,583 | 6,846 ▲ 4.0% |
| OPM %Derived | 20.75% | 20.34% |
| 2,107 | 2,097 ▼ 0.5% | |
| Profit Before Tax (PBT) | 5,098 | 5,110 ▲ 0.2% |
| 1,583 | 1,609 ▲ 1.7% | |
| Effective Tax %Derived | 31.05% | 31.48% |
| Total Profit for Period | 3,484 | 3,503 ▲ 0.6% |
| Less: Non-controlling Interests | -2 | -2 ▲ 22.9% |
| Net Profit (Owner's PAT)Derived | 3,486 | 3,505 ▲ 0.5% |
| Net Profit Margin %Derived | 10.99% | 10.41% |
| PAT Growth YoY %Derived | 9.86% | 0.54% |
| Earnings Per Share (EPS ₹) | 60.02 | 60.34 ▲ 0.5% |
| Diluted Shares Outstanding (Cr) | 58 | 58 ▲ 0.0% |
| Share of Profit from Associates/JVs | -32 | 2 ▲ 104.8% |
| Other Comprehensive Income (Net of Tax) | 304 | 1,965 ▲ 547.3% |
| Total Expenses (incl. D&A & Interest) | 27,248 | 29,035 ▲ 6.6% |
| Material Cost % of RevenueDerived | 33.84% | 30.62% |
| Employee Cost % of RevenueDerived | 14.11% | 15.42% |
| Other Cost % of RevenueDerived | 24.08% | 24.15% |
| Interest Coverage (x)Derived | 10.79x | 13.20x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 16,500 | 19,564 ▲ 18.6% | 23,099 ▲ 18.1% | 24,775 ▲ 7.3% | 23,455 ▼ 5.3% | 24,855 ▲ 6.0% | 29,002 ▲ 16.7% | 31,724 ▲ 9.4% | 33,653 ▲ 6.1% | |
| Sales Growth YoY %Derived | — | 18.57% | 18.07% | 7.26% | -5.32% | 5.97% | 16.68% | 9.39% | 6.08% | |
| Other Income | 102 | 116 ▲ 13.4% | 86 ▼ 25.5% | 381 ▲ 341.8% | 320 ▼ 15.9% | 291 ▼ 9.3% | 557 ▲ 91.8% | 622 ▲ 11.6% | 492 ▼ 20.9% | |
| Total Income | 16,602 | 19,679 ▲ 18.5% | 23,185 ▲ 17.8% | 25,155 ▲ 8.5% | 23,776 ▼ 5.5% | 25,146 ▲ 5.8% | 29,559 ▲ 17.6% | 32,346 ▲ 9.4% | 34,145 ▲ 5.6% | |
6,753 | 8,713 ▲ 29.0% | 9,735 ▲ 11.7% | 9,902 ▲ 1.7% | 10,140 ▲ 2.4% | 11,293 ▲ 11.4% | 12,603 ▲ 11.6% | 13,026 ▲ 3.4% | 13,488 ▲ 3.5% | ||
| Gross ProfitDerived | 9,747 | 10,851 ▲ 11.3% | 13,363 ▲ 23.2% | 14,872 ▲ 11.3% | 13,315 ▼ 10.5% | 13,562 ▲ 1.9% | 16,399 ▲ 20.9% | 18,697 ▲ 14.0% | 20,165 ▲ 7.8% | |
| Gross Margin %Derived | 59.07% | 55.46% | 57.85% | 60.03% | 56.77% | 54.56% | 56.54% | 58.94% | 59.92% | |
5,975 | 6,959 ▲ 16.5% | 8,539 ▲ 22.7% | 9,539 ▲ 11.7% | 8,928 ▼ 6.4% | 9,843 ▲ 10.2% | 10,556 ▲ 7.2% | 12,115 ▲ 14.8% | 13,319 ▲ 9.9% | ||
| EBITDA (Operating Profit)Derived | 3,772 | 3,892 ▲ 3.2% | 4,825 ▲ 24.0% | 5,333 ▲ 10.5% | 4,387 ▼ 17.7% | 3,719 ▼ 15.2% | 5,843 ▲ 57.1% | 6,583 ▲ 12.7% | 6,846 ▲ 4.0% | |
| OPM %Derived | 22.86% | 19.89% | 20.89% | 21.53% | 18.70% | 14.96% | 20.15% | 20.75% | 20.34% | |
636 | 743 ▲ 16.8% | 1,100 ▲ 48.2% | 3,944 ▲ 258.5% | 1,047 ▼ 73.5% | 1,385 ▲ 32.3% | 1,620 ▲ 16.9% | 2,107 ▲ 30.1% | 2,097 ▼ 0.5% | ||
| Profit Before Tax (PBT) | 3,238 | 3,089 ▼ 4.6% | 3,758 ▲ 21.7% | 7,399 ▲ 96.9% | 3,404 ▼ 54.0% | 2,624 ▼ 22.9% | 4,397 ▲ 67.6% | 5,098 ▲ 15.9% | 5,110 ▲ 0.2% | |
818 | 727 ▼ 11.2% | 914 ▲ 25.7% | 2,010 ▲ 120.0% | 726 ▼ 63.9% | 685 ▼ 5.6% | 1,211 ▲ 76.8% | 1,583 ▲ 30.7% | 1,609 ▲ 1.7% | ||
| Effective Tax %Derived | 25.27% | 23.53% | 24.31% | 27.16% | 21.32% | 26.10% | 27.54% | 31.05% | 31.48% | |
| Total Profit for Period | 2,423 | 2,365 ▼ 2.4% | 2,830 ▲ 19.7% | 5,334 ▲ 88.5% | 2,647 ▼ 50.4% | 1,928 ▼ 27.2% | 3,169 ▲ 64.4% | 3,484 ▲ 9.9% | 3,503 ▲ 0.6% | |
| Less: Non-controlling Interests | -0 | -0 ▲ 11.5% | -1 ▼ 534.8% | -1 ▲ 30.1% | -1 ▼ 2.0% | 0 ▲ 114.4% | -4 ▼ 2766.7% | -2 ▲ 42.3% | -2 ▲ 22.9% | |
| Net Profit (Owner's PAT)Derived | 2,423 | 2,365 ▼ 2.4% | 2,831 ▲ 19.7% | 5,335 ▲ 88.4% | 2,648 ▼ 50.4% | 1,928 ▼ 27.2% | 3,173 ▲ 64.6% | 3,486 ▲ 9.9% | 3,505 ▲ 0.5% | |
| Net Profit Margin %Derived | 14.69% | 12.09% | 12.26% | 21.53% | 11.29% | 7.75% | 10.94% | 10.99% | 10.41% | |
| PAT Growth YoY %Derived | — | -2.41% | 19.72% | 88.45% | -50.36% | -27.21% | 64.62% | 9.86% | 0.54% | |
| Earnings Per Share (EPS ₹) | 41.36 | 40.36 ▼ 2.4% | 48.32 ▲ 19.7% | 91.05 ▲ 88.4% | 45.20 ▼ 50.4% | 32.90 ▼ 27.2% | 54.15 ▲ 64.6% | 60.02 ▲ 10.8% | 60.34 ▲ 0.5% | |
| Diluted Shares Outstanding (Cr) | 59 | 59 ▲ 0.0% | 59 ▲ 0.0% | 59 ▲ 0.0% | 59 ▲ 0.0% | 59 ▲ 0.0% | 59 ▲ 0.0% | 58 ▼ 0.9% | 58 ▲ 0.0% | |
| Share of Profit from Associates/JVs | 3 | 3 ▼ 14.0% | -15 ▼ 661.9% | -55 ▼ 264.9% | -31 ▲ 43.6% | -12 ▲ 62.7% | -17 ▼ 47.0% | -32 ▼ 84.7% | 2 ▲ 104.8% | |
| Other Comprehensive Income (Net of Tax) | 150 | -4 ▼ 102.8% | 287 ▲ 6936.2% | 5 ▼ 98.3% | 262 ▲ 5420.0% | 736 ▲ 181.1% | 99 ▼ 86.5% | 304 ▲ 206.2% | 1,965 ▲ 547.3% | |
| Total Expenses (incl. D&A & Interest) | 13,364 | 16,591 ▲ 24.1% | 19,427 ▲ 17.1% | 17,757 ▼ 8.6% | 20,372 ▲ 14.7% | 22,522 ▲ 10.6% | 25,162 ▲ 11.7% | 27,248 ▲ 8.3% | 29,035 ▲ 6.6% | |
| Material Cost % of RevenueDerived | 34.12% | 38.06% | 33.44% | 33.57% | 31.43% | 38.83% | 37.16% | 33.84% | 30.62% | |
| Employee Cost % of RevenueDerived | 12.91% | 13.21% | 13.94% | 14.27% | 14.71% | 14.17% | 13.53% | 14.11% | 15.42% | |
| Other Cost % of RevenueDerived | 23.30% | 22.36% | 23.03% | 24.23% | 23.35% | 25.43% | 22.87% | 24.08% | 24.15% | |
| Interest Coverage (x)Derived | 41.36x | 19.82x | 24.15x | 57.43x | 67.03x | 17.61x | 14.92x | 10.79x | 13.20x |
Aurobindo Pharma segment analysis : revenue and profit mix.
Disclosed business segments at Aurobindo Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Aurobindo Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Aurobindo Pharma Limited.
Our AI distills the core fundamental drivers supporting Aurobindo Pharma Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Aurobindo Pharma Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Low debt-to-equity ratio of 0.0021x ensures exceptional financial stability and flexibility.
Operating margin of 15.21% demonstrates solid pricing power and operational efficiency.
Promoter holding of 51.82% reflects strong insider confidence and long-term commitment.
Positive operating cash flow of ₹2,885 Cr supports liquidity and dividend sustainability.
Market cap of ₹0.90 LCr ranks among top pharmaceutical peers, indicating significant scale.
Key Risks.
Latest quarterly EPS grew only 2.0% YoY, indicating sluggish earnings expansion despite revenue.
TTM EPS grew only 1.9% YoY, signaling muted earnings momentum in competitive markets.
Dividend yield of 0.25% is minimal, limiting income appeal for yield-focused investors.
FII holdings fell from 24.12% to 15.33%, signaling foreign investor caution and selling pressure.
ROCE of 12.80% trails peer median of 20.30%, suggesting suboptimal capital deployment efficiency.
Flip Conditions.
Valuation risk. a P/E above 34 (~0.8× the sector multiple of 40.5) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Aurobindo Pharma Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Aurobindo Pharma Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Aurobindo Pharma Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Aurobindo Pharma Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Aurobindo Pharma Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Aurobindo Pharma Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Aurobindo Pharma Limited stood at 39.7% of traded volume, against a 20-day average of 46.8%.
Aurobindo Pharma announcements: results, concalls, ratings, M&A.
Filings Aurobindo Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Aurobindo Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 230 documents below.
Acquisition
Aurobindo Pharma Limited has informed the Exchange about incorporation of a new wholly owned stepdown subsidiary in Indonesia.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Aurobindo Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
General Updates
Aurobindo Pharma Limited has informed the Exchange about completion of of transfer of Company s domestic branded generic pharmaceutical formulations…
Acquisition
Intimation of completion of Lannett acquisition by Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company.
General Updates
Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Auroactive Pharma Private Limited, a wholly owned…
Investor decks & rating reports.
Aurobindo Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Aurobindo Pharma has declared, sequenced by announce and record date.
Aurobindo Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Aurobindo Pharma Limited: business, sector, key facts.
What Aurobindo Pharma Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Aurobindo Pharma Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: AUROPHARMA, BSE: 524804.
Aurobindo Pharma Limited is a global biopharmaceutical company with a significant presence in the manufacturing and distribution of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Their operations span several continents, including India, the United States, Europe, and Puerto Rico, showcasing a broad international reach.
The company's product portfolio is extensive and diverse, encompassing a wide range of dosage forms. These include oral solids and liquids, injectables, and vaccines. They also offer over-the-counter (OTC) medications, demonstrating a commitment to serving various healthcare needs. Beyond formulations, Aurobindo Pharma is a major player in the API market, producing crucial ingredients for numerous drugs.
Aurobindo's API production includes a variety of complex molecules and biologicals. They manufacture biosimilars (similar to biological drugs), biocatalysts, peptides, and hormones, demonstrating expertise in advanced pharmaceutical technologies. Their therapeutic focus covers a broad spectrum of medical areas, such as central nervous system disorders, cardiovascular diseases, respiratory illnesses, infections (antibiotics and antiretrovirals), diabetes, gastroenterological issues, cancer (oncology), and dermatological conditions.
A key aspect of Aurobindo Pharma's business is its commitment to addressing significant global health challenges. This is evident in their production of antiretroviral drugs, specifically targeting the needs of HIV-positive adults and children. Furthermore, their contract research and manufacturing services extend across the entire drug lifecycle, from clinical stages to full-scale production. This includes specialized services for the manufacturing of sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta-lactams.
Established in 1986 and headquartered in Hyderabad, India, Aurobindo Pharma has a long history of innovation and growth in the pharmaceutical industry. Their integrated approach, encompassing both formulation and API production, along with their global reach and commitment to various therapeutic areas, positions them as a significant player in the worldwide pharmaceutical market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Aurobindo Pharma Limited (AUROPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Aurobindo Pharma Limited (AUROPHARMA)?
The current share price of Aurobindo Pharma Limited (AUROPHARMA) is ₹1,536.2. Today, the stock has declined by ₹43.50 (2.75%), trading in a range of ₹1,515 to ₹1,564. The stock opened at ₹1,564 with a trading volume of 13,06,543 shares.
02Is Aurobindo Pharma Limited stock a good investment for long-term?
Aurobindo Pharma Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹88,346.4 crores, P/E ratio of 26.03, ROE of 10.10%, and ROCE of 12.80%. The dividend yield stands at 0.26%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Aurobindo Pharma Limited stock?
The 52-week high price of Aurobindo Pharma Limited (AUROPHARMA) is ₹1,636.8, while the 52-week low is ₹1,016.1. Currently trading at ₹1,536.2, the stock is 83.8% away from its 52-week low and 6.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Aurobindo Pharma Limited stock at the current price?
Whether to buy Aurobindo Pharma Limited stock at ₹1,536.2 depends on multiple factors. The stock is currently trading with a P/E ratio of 26.03 and P/B ratio of 2.41. Today's performance shows a loss of 2.75%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Aurobindo Pharma Limited and when is the next dividend?
Aurobindo Pharma Limited offers a dividend yield of 0.26%, which means for every ₹100 invested at the current price of ₹1,536.2, you can expect to receive approximately ₹0.26 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Aurobindo Pharma Limited?
Aurobindo Pharma Limited's key financial metrics include: P/E Ratio: 26.03, P/B Ratio: 2.41, ROE: 10.10%, ROCE: 12.80%, Dividend Yield: 0.26%, EPS: ₹60.36, Book Value: ₹652.31, and Debt-to-Equity: 0.21. The company's market cap stands at ₹88,346.4 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Aurobindo Pharma Limited stock performing today in the market?
Aurobindo Pharma Limited stock opened at ₹1,564 and is currently trading at ₹1,536.2, showing a decline of ₹43.50 (2.75%). The intraday high is ₹1,564 and low is ₹1,515. The trading volume stands at 13,06,543 shares, indicating strong market participation today.
08What is the P/E ratio of Aurobindo Pharma Limited and what does it indicate?
Aurobindo Pharma Limited has a Price-to-Earnings (P/E) ratio of 26.03, which means investors are willing to pay ₹26.03 for every ₹1 of earnings. With an EPS of ₹60.36, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Aurobindo Pharma Limited (AUROPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.